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Abstract Introduction
We investigated whether minor histocompatibility (mH) an-
tigen-specific cytotoxic T lymphocytes (CTL)-can discrimi-
nate between leukemic hematopoietic progenitor cells (leu-
kemic-HPC) from AML or CML patients, the HPC from
their remission bone marrow (remission-HPC), and normal
HPC from their HLA-identical sibling bone marrow donor
(donor-HPC). Specific lysis by CD8+ CTL clones was ob-
served not only of the leukemic-HPC but also of the donor-
HPC in 3/4 patient/donor combinations expressing mH an-
tigen HA-1, 3/5 combinations expressing mH antigen HA-
2, 2/3 combinations expressing mH antigen HA-3, and 2/2
combinations expressing mH antigen HY-Al. In four pa-
tient/donor combinations the recognition of the donor-HPC
was clearly less than of the leukemic-HPC, indicating differ-
ential susceptibility to lysis by these mH CTL clones. In
addition, differential recognition of leukemic-HPC and re-
mission-HPC within seven patients was analyzed. In one
patient expressing the HA-2 antigen on the leukemic cells
the recognition of the remission-HPC was clearly less than
of the leukemic-HPC. One CD4 + CTL clone showed specific
lysis of the leukemic-HPC from an AML patient and a CML
patient as well as ofnormal remission-HPC and donor-HPC.
These results illustrate that in general CD8+ and CD4+ mH
antigen specific CTL clones do not differentially recognize
leukemic-HPC and normal-HPC. However, differences in
susceptibility to lysis of malignant versus normal cells may
contribute to a differential GVL effect. (J. Cln. Invest. 1995.
96:877-883.) Key words: leukemia * clonogenic (leuke-
mic) hematopoietic progenitor cells * differential recogni-
tion * graft-versus-host disease * graft-versus-leukemia reac-
tivity
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myeloid leukemia; CTL, cytotoxic T lymphocyte; GVHD, graft-versus-
host disease; GVL, graft-versus-leukemia; HPC, progenitor cells; mH,
minor histocompatibility.
Allogeneic bone marrow transplantation (BMT)' has been asso-
ciated with an immune-mediated anti-leukemic effect, the graft-
versus-leukemia (GVL) effect. T lymphocytes from the donor
marrow graft may be responsible for this GVL effect since T
cell depletion of the graft is correlated with an increased risk
of leukemic relapse after BMT (1-6). Since a correlation has
been found between the occurrence of GVHD with a decreased
risk of leukemic relapse after BMT (2, 4, 7-12) it is hypothe-
sized that the donor-derived T lymphocytes that cause GVHD
may also be the mediators of the GVL reactivity. More recently,
direct clinical evidence for a GVL effect has been demonstrated
by several investigators (13-15). Hematological and cytoge-
netic remissions after leukocyte transfusion from the original
marrow donor for Philadelphia-positive patients with chronic
myeloid leukemia (CML) who relapsed after allogeneic BMT
have been reported. In the etiology of both GVL and GVHD
minor histocompatibility (mH) antigens may play an important
role (16-20). In vitro, we have demonstrated that CD8+ mH
antigen specific cytotoxic T lymphocyte (CTL) clones gener-
ated from patients with GVHD after allogeneic BMT, are capa-
ble of antigen-specific lysis of freshly obtained leukemic cells,
and of antigen specific growth inhibition of the clonogenic leu-
kemic precursor cells (leukemic-HPC) from unrelated patients
(21, 22). Furthermore, we have shown that CD8+ mH antigen
specific CTL clones can recognize mH antigens on hematopoi-
etic progenitor cells (HPC) (23-25). Recently, we have dem-
onstrated that mH antigen specific CD4+ CTL clones could be
generated from a patient with chronic myeloid leukemia (CML)
with acute GVHD grade HI-IV after allogeneic BMT (Faber,
L.M., S.A.P. van Luxemburg-Heijs, W.F.J. Veenhof, R. Wil-
lemze, and J.H.F. Falkenburg, manuscript submitted for publi-
cation). As previously illustrated, some mH-specific CTL
clones recognize both hematopoietic and non-hematopoietic
cells, whereas other reactivities appear to be restricted to cell
types of hematopoietic origin (26). In this study we investigated
whether mH antigen specific CD8+ or CD4+ CTL clones gen-
erated from patients with GVHD differentially recognize leuke-
mic-HPC from patients with AML or CML and normal HPC
from their HLA genotypically identical sibling donor. Further-
more, we evaluated whether these mH specific CTL clones can
discriminate between leukemic-HPC and the remission progeni-
tor bone marrow cells (remission-HPC), within the same pa-
tient with AML. We demonstrate that although in general these
CD8+ and CD4+ mH antigen specific CTL clones do not differ-
entially recognize leukemic-HPC and normal HPC, differences
in susceptibility to lysis of malignant versus normal cells can
be observed suggesting that in some patients this may result in
a specific GVL effect.
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Methods
Generation of mH antigen-specific CTL clones. CD8+ mH antigen-
specific CTL clones with specific cytotoxicity for the mH specificity
HA- 1, HA-2, or HA-3 were generated from patients after allogeneic
BMT as previously described ( 16, 27). HA-1 and HA-2-specific recog-
nition is restricted by HLA-A2, HA-3 recognition is restricted by HLA-
Al. As control effector cells CTL clones with anti-HLA-A2 or anti-
HLA-A1 specificity (positive controls) or a HLA-B8 restricted mH
antigen specificity (negative control) were used. The frequency of the
mH antigens recognized by the HA-1, HA-2, HA-3 specific CTL clones
studied in a random population on the lymphocytes from individuals
expressing the relevant class I restriction molecule was 69% for HA-1,
95% for HA-2, and 88% for HA-3 (27). The HLA-Al -restricted HY-
specific CTL clone used in this study was generated from a female
patient who rejected a T-lymphocyte-depleted bone marrow graft from
her HLA-phenotypically identical donor (28).
The CD4+ mH antigen-specific HLA-DR2 restricted CTL clones,
clone 11 was generated from a patient with CML with acute GVHD
grade HI-IV after allogeneic BMT (Faber, L.M., S.A.P. van Luxemburg-
Heijs, WJ.F. Veenhof, R. Willemze, and J.H.F. Falkenburg, manuscript
submitted for publication). The second CD4+ CTL clone used, clone
S, was generated before HLA-identical allogeneic BMT from the sibling
donor directed against the leukemic cells from the recipient (29). Clone
S, showed HLA-DR2 restricted lysis of the recipient leukemic cells and
DR2 positive EBV transformed B cells (EBV-LCL). PHA stimulated
T lymphocytes from both recipient and donor were not recognized by
this clone.
The CTL clones were cultured in RPMI medium supplemented with
15% pooled human serum and human recombinant interleukin-2 (r-IL-
2) 300 IU/ml and expanded by weekly restimulation with irradiated,
specific mH antigen positive EBV-LCL plus freshly isolated peripheral
blood mononuclear cells (MNC) from random donors. The CTL clones
were stored in liquid nitrogen. The day before use the clones were
thawed and cultured overnight in RPMI plus 15% pooled human serum
and rIL-2 300 IU/ml.
5"Cr release assay. Standard 51Cr release assays were performed as
described previously (29, 30). As effector cells, the CTL clones were
used; as target cells T lymphocyte populations, leukemic cells, remission
bone marrow from the patient, bone marrow from the donor or EBV-
LCL's were used. Target cells, labelled with 51Cr and effector cells were
incubated at various ratio's. To measure spontaneous release of 5'Cr,
target suspensions were analyzed in the absence of effector cells. Maxi-
mum release was determined by adding 0.1 ml of the target suspension
to 0.1 ml Zaponine solution. The percentage specific lysis obtained in
a 51Cr release assay was determined as follows: 100% x (experimental
release cpm - spontaneous release cpm) / (maximum release cpm
- spontaneous release cpm).
Target cells. After informed consent leukemic cells were collected
from the bone marrow of patients with AML or CML at diagnosis.
Patients with > 95% morphologically recognizable leukemic cells in
their bone marrow were selected. Remission bone marrow was obtained
in complete remission from the patients with AML after treatment with
daunorubicin and arabinosyl-cytosine (Ara-C) (induction course) and
subsequently with high dose Ara-C and amsacrin (consolidation
course). (Normal) donor bone marrow was obtained from the HLA-
identical sibling donor of patients who were transplanted. The cells were
centrifuged over Ficoll Isopaque (density 1.077 g/cm3, 1,000 g, 20
min) and the interphase cells were harvested, and cryopreserved in
liquid nitrogen. Before use, the cells were thawed, washed twice, and
resuspended in RPMI containing 15% prescreened AB serum.
T lymphocytes were expanded by stimulating 107 peripheral blood
MNC from patient or donor with 0.2% phytohemagglutinin (PHA)
(Difco Laboratories, Detroit, MI) in RPMI plus 15% human AB serum
for three days. The cells were then washed and further cultured in the
absence of PHA in the presence of human rIL-2 300 IU/ml, for at least
three more days before testing.
Stable EBV-LCL were established by in vitro transformation of 107
peripheral blood MNC with EBV supernatant. The cells were washed
and further cultured in RPMI plus 10% FCS (GIBCO BRL, Gaithers-
burg, MD).
Cell-mediated inhibition of clonogenic (leukemic) progenitor cell
growth (31). To determine specific reactivity of the anti-mH CTL clones
with clonogenic leukemic progenitor cells (leukemic-HPC), remission
bone marrow progenitor cells (remission-HPC) and donor bone marrow
progenitor cells (donor-HPC) 3.l04 target cells (leukemic cells or bone
marrow cells) in 0.1 ml medium consisting of Iscove's Modified Dulbec-
co's Medium (IMDM) plus 15% human AB serum was mixed with
irradiated (l5Gy) CTL at effector/target (E/T) ratio 1:1. The cell mix-
ture was centrifuged (1,000 g, 15 s) to establish cell-cell contact be-
tween CTL and the target cells, and then preincubated for 4 h at 37TC.
After incubation the cells were resuspended and cultured as a single
cell suspension at a concentration of 3.104 target cells/ml in a 30-mm
culture dishes in 1 ml IMDM containing 10% prescreened human AB
serum, 2 U/mi erythropoietin (Cilag AG International, Zug, Switzer-
land), 10 ng/mi GM-CSF (Sandoz Ltd., Basle, Switzerland), 10 ng/
ml G-CSF (Amgen, CA), 50 ng/ml SCF (Amgen, CA), 25 ng/mi IL-
3 (Sandoz Ltd., Basle, Switzerland), 0.47 grams/liter human transferrin
(Behringwerke AG, Marburg, Germany) saturated with FeCl3, 5. 10-5
mol/l mercaptoethanol, and methylcellulose (Methocel 4000 cps; Fluka,
Freiburg, Germany) at a final concentration of 1.1% (wt/vol). The cells
were incubated in a fully humidified atmosphere of 5% CO2 and 37°C.
After 14 d of culture, the number of leukemic colonies (defined as
aggregates of at least 50 undifferentiated cells), CFU-G colonies (de-
fined as aggregates of > 50 neutrophilic or eosinophilic granulocytes),
CFU-M (defined as aggregates > 50 monocytic cells), and BFU-E
colonies (defined as colonies consisting of > 50 hemoglobinized cells)
were scored, using a inverted microscope. The colony growth in the
presence of effector cells is expressed as percentage of growth of the
number of colonies observed in the untreated (grown in the absence of
effector cells) control culture. To control for antigen-nonspecific inhibi-
tion of colony growth due to secretion of humoral inhibitory factors
into the culture medium, effectors were also plated together with the
target cells at the same E/T ratios directly in the semisolid medium,
without 4 h preincubation, to prevent cell-cell contact. The colony
growth in the presence of effector cells, without 4 h preincubation, is
expressed as percentage of growth of the number of colonies observed
in the untreated (grown in the absence of effector cells) control culture.
Specific cell-mediated growth inhibition was determined as follows: 100
- (colony growth in the presence of cell-cell contact/colony growth in
the absence of cell-cell contact) x 100%. Specific cell-mediated growth
inhibition of < 20% was considered negative. Inhibition of 20-50%
was considered minor inhibition, inhibition of > 50% positive.
An increased growth of CFU-M colonies was observed when the
CD4+ CTL clones, clone 11 and clone S, were used as effector cells,
compared to the untreated control cultures. Therefore a conditioned
medium was made from both CD4+ clones and added to all culture
dishes at a final concentration of 20% when the corresponding CD4+
CTL clone was used as effector cell.
For cytogenetic analysis of the growing colonies a clonogenic assay
of the leukemic cells from patients 8 and 11 was performed. 106 cells
were cultured under the same conditions as described and were harvested
after 7 d of culture. The methylcellulose was removed by washing with
RPMI and the cells were resuspended in the original culture medium
without methylcellulose and cultured in suspension in 50 ml tissue
culture flasks for 18 hours at 37°C, 5% C02, 98% humidity. After
colcemid arrest, metaphase spreads were prepared according to standard
techniques. At least 30 metaphases were examined for each chromo-
somal analysis.
Results
Leukemic cells from seven patients with AML of various sub-
types according to the FAB classification and from four patients
with CML in chronic phase were analyzed. Only patients ex-
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Table I. Characteristics of the Leukemic Cells and Colony
Growth of the Leukemic Precursor Cells per 3.10' Plated Cells
HLA-Type FAB-class. Karyotype Leuk-HPC
1. A2 AML M4/5 46XY del(19)(pl3) 26
2. A2 AML M2 46XY trisomie 10 36
3. A1, B8 AML M5 46XY 286
4. Al, A2, B8 CML CP* 46XY t(9;22) 118
5. Al, A2, B8 CML CP* 46XY t(9;22) 223
6. A2 CML CP* 46XX t(9;22) 212
7. Al, B8 AML M5 46XY 383
8. A2 AML M2 46XX t(8;21) 366
9. A2 AML MO 46XX 80
10. A2, DR2 AML M2 46XY 149
11. DR2 CML CP* 46XX t(9;22) 353
* Chronic phase. For patient
ments.
11, 1.10' cells were plated in the experi-
pressing HLA-Al,-A2, and/or HLA-DR2 on their lymphocytes
were selected for this study, corresponding with the HLA-re-
striction element from the mH antigen-specific CTL clones
used. Table I shows the characteristics of the leukemic samples
from the I1 patients used. Cytogenetic analysis of the growing
colonies from patients 8 and 11 after 7 d of culture showed that
93% of the metaphases contained the t(8;21) translocation and
100% of the metaphases contained the t(9;22) translocation,
respectively. Furthermore, the high percentage (> 95%) of the
leukemic cells in the samples used excluded the possibility of
a significant contribution of colonies derived from residual nor-
mal progenitor cells present in the cell suspension.
Table H shows the specific reactivity of the CD8+ and
CD4+ mH CTL clones with the T lymphocytes or EBV-LCL
from the patients and their HLA-identical sibling donors. In
general the mH specific CTL clones did recognize the T lym-
phocytes from both the patient and HLA-identical donor ex-
pressing the relevant mH antigen. However in two patient/do-
nor combinations differences in lysis of T lymphocytes from
the patient versus T lymphocytes from the donor by two CTL
clones was observed. The HA-I and HA-3 specific CTL clones
showed specific lysis of the T lymphocytes from patient 1 and
4, respectively, but not of the T lymphocytes from their HLA-
identical donor, illustrating that the specific mH antigen was
not expressed by the T lymphocytes from the donors. When
mH antigen-specific lysis of the T lymphocytes was observed
the leukemic cells from the patients and the bone marrow cells
from their HLA-identical sibling donor were further tested in
the cell-mediated cytotoxicity assays described.
HLA-A2 and HLA-AJ restricted recognition by the mH spe-
cific CTL clones. The HLA-A2 restricted anti-HA-i and anti-
HA-2 CTL clone and the HLA-A1 restricted anti-HA-3 and
anti-HY CTL clone showed similar cytotoxicity against the leu-
kemic cells from the patients and the normal bone marrow cell
from their HLA-identical sibling donor as measured in the 51Cr
release assay (Table HI). When these CTL clones were further
tested in the clonogenic cytotoxicity assay, similar results were
observed from the HA-1, HA-3, and HY-Al specific CTL
clones (Table IV). When the leukemic cells from the patient
and the normal bone marrow cells from the HLA-identical do-
nor were recognized in the 5"Cr release assay, mH antigen-
specific growth inhibition was observed of both the leukemic-
HPC from the patient and HPC from the HLA-identical donor.
Different results were obtained from the HLA-A2 restricted
HA-2 specific CTL clone. This CTL clone recognized the HA-
2 antigen expressed on the T lymphocytes and leukemic cells
from patient 1 and 2, and the T lymphocytes and normal bone
marrow cells from their HLA-identical donor in the 5"Cr release
assay. However, in the clonogenic assay the HA-2 specific CTL
clone inhibited the leukemic-HPC from patient 1 and 2, but
showed lower inhibition of the HPC from their HLA-identical
donor.
In conclusion the HA-1, HA-2 and HA-3 specific CTL
clones in general recognize both normal and leukemic HPC,
but may discriminate between leukemic-HPC from the patient
and normal HPC from the HLA-identical sibling donor.
To investigate whether these mH antigen specific CTL
clones differentially recognize leukemic and normal precursor
cells from individual patients with AML (Table I), the leuke-
Table II. Reactivity of mH-specific CTL Clones with Normal Lymphocytes from the Patients and Their HLA Genotypically
Identical Donor
Patient/HLA-identical donor
1 \ 2 3 4 5 6
CTL-clone P D P D P D P D P D P D
HA-1 ++ -- ++ ++ __ __ ++ ++ ++ ++ __ __
HA-2 ++ + ++ ++ -- -- ++ ++ ++ ++ ++ ++
HA-3 _ ++ ++ ++ ++
mH-B8 -- -- -- -- -- -- -- -- -- -- -- --
HY-Al -- -- -- -- ++ ++ ++ ++ * * * *
a-Al -- -- -- -- ++ ++ ++ ++ ++ ++ -- --
a-A2 ++ ++ ++ ++ __ __ ++ ++ ++ ++ ++ ++
Specific lysis of PHA stimulated T lymphocytes from the patients (P), generated from remission bone marrow cells of the AML patients and from
the leukemic bone marrow cells of the CML patients, and from their HLA genotypically identical sibling donor (D) in a 51Cr release assay at ET
ratio 3:1. (-) 0-10% lysis; (+) 10-25% lysis; (++) 25-100% lysis; *not tested. The anti-HLA-Al and anti-HLA-A2 CTL clones were used as
positive controls (specific lysis > 25%). The HLA-B8 restricted mH specific CTL clone was used as negative control (specific lysis < 10%).
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Table III. Specific Lysis of the Leukemic Cells from the Patients and of the Normal Bone Marrow Cells from Their HLA Genotypically
Identical Sibling Donor
Patient/HLA-identical donor
1 2 3 4 5 6
CTL-clone P D P D P D P D P D P D
HA-1 35 -2 50 61 * * 35 39 57 29 * *
HA-2 20 26 39 51 * * 21 29 70 35 24 36
HA-3 * * * * 13 30 30 -4 92 51 * *
HY-Al * * * * 25 27 35 46 * * * *
Specific lysis of the leukemic cells from the patients (P) and of the normal bone marrow cells from their HLA genotypically identical sibling donor
(D) was measured using a standard 5'Cr release assay in duplicate at E/T ratio 3:1. Data are expressed as percentage specific lysis. *Data not
applicable because the restriction element was not present. The anti-HLA-Al and anti-HLA-A2 CTL clones (data not shown) were used as positive
controls (specific lysis > 25%), the HLA-B8 restricted mH-specific CTL clone as a negative control (specific lysis < 10%).
mic-HPC and the remission-HPC from the same patient was
further tested in the clonogenic cytotoxicity assay when mH
antigen-specific lysis of the T lymphocytes was observed. In
general mH antigen-specific growth inhibition was observed of
both the leukemic-HPC and remission-HPC (Table V). Differ-
ent results were obtained from the HLA-A2 restricted anti-HA-
2 specific CTL clone. This CTL clone recognized the HA-2
antigen expressed on the T lymphocytes, the leukemic cells and
remission bone marrow from patients 1,2,8,9, and 10 in the 5'Cr
release assay (data not shown). HA-2 specific growth inhibition
by this CTL clone was observed of both the leukemic-HPC and
remission-HPC from patients 2,8,9, and 10. However, the HA-
2 specific CTL clone inhibited the leukemic-HPC, but repeat-
edly not the remission-HPC from patient 1 (the experiment was
repeated three times at different days), indicating differential
susceptibility to lysis by this CTL clone (Table V).
In conclusion from the four tested CD8+ mH specific CTL
clones only one CTL clone, the HA-2 specific CTL clone dis-
criminated between leukemic-HPC cells and remission-HPC
from one patient.
DR-2 restricted recognition by the CD4+ CTL clones. The
two DR-2 restricted CTL clones, clone 11 and clone S recog-
nized the EBV-LCL from AML patient 10 (Table VI). In a
51Cr release assay these two CTL clones showed no specific
lysis of the leukemic cells and remission bone marrow (remis-
sion-BM) from patient 10. The low specific lysis of the leuke-
mic cells from patient 10 could not be explained by a low DR-
expression of these leukemic cells, since the DR expression was
high as measured by FACS analysis. However when the CTL
clone 11 was further tested in the cell-mediated clonogenic
assay mH antigen specific growth inhibition was observed of
both the leukemic-HPC and the remission-HPC from patient
10. No differential recognition by this CTL clone was observed.
Clone S showed no or only minor specific growth inhibition of
the leukemic-HPC and remission HPC from patient 10 in the
clonogenic assay. The two DR-2 restricted CTL clones, clone
11 and clone S both recognized the EBV-LCL from patient 11
and her HLA-genotypically identical donor (Table VI). Clone
11 showed low but significant specific lysis of the leukemic
cells from patient 11 in the 5"Cr release assay in three separate
experiments (19±4%). This was probably in part due to the
relatively low expression of class II molecules on the CML
cells (< 50%). When this CTL clone was further tested in
the cell-mediated clonogenic assay mH antigen specific growth
inhibition was observed of both the leukemic-HPC and the do-
nor-HPC from patient 11. Clone S, the CTL clone that recog-
nized the EBV-LCL from patient 11 and donor 11, and showed
minor recognition of the leukemic cells from patient 11 in the
Table IV. HLA-AJ and HLA-A2 Restricted Growth Inhibition of Clonogenic Leukemic Precursor Cells from the Patients and of the
Hematopoietic Progenitor Cells from Their HLA Genotypically Identical Sibling Donor
Patient/HLA-identical donor
1 2 3 4 5 6
CTh-clone P D P D P D P D P D P D
HA-1 80 17 80 83 * * 95 87 76 85 * *
HA-2 60 31 88 49 * * 58 54 69 65 50 53
HA-3 * * * * 75 71 99 1 94 99 * *
HY-Al * * * * 73 86 99 99 * * * *
HLA-A1 and HLA-A2 restricted mH specific growth inhibition of clonogenic leukemic precursor cells from patients with AML or CML (P) and
of normal hematopoietic precursor cells (BFU-E + CFU-GM) from their HLA-identical donor (D). E/T ratio 1:1 is shown. Similar results were
obtained at E/T ratio's 0.3:1 and 0.1:1, respectively. The anti-HLA-Al and anti-HLA-A2 CTL clones were used as positive controls (specific cell
mediated colony growth inhibition > 50%), the HLA-B8 restricted mH specific CTL clone as a negative control (specific cell-mediated colony
growth inhibition < 20%).
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Table V. HLA-AJ and HLA-A2 Restricted Growth Inhibition of the Clonogenic Leukemic Progenitor Cells and the Remission
Hematopoietic Progenitor Cells from the Same Patient
Patient
1 2 3 7 8 9 10
CTL-clone L R L R L R L R L R L R L R
HA-1 80 57 80 96 * * * * 2 9 1 30 4 1
HA-2 60 1 88 80 * * * * 72 55 78 74 53 89
HA-3 * * * * 75 75 64 58 * * * * * *
HY-Al * * * * 73 90 70 98 * * * * * *
Growth inhibition of clonogenic leukemic precursor cells (L) and hematopoietic progenitor cells in remission (R) from the same AML patient by
the HLA-Al, HLA-A2 and HLA-DR2 restricted mH specific CTL clones. E/T ratio 1:1 is shown. Similar results were obtained at E/T ratio's 0.3:1
and 0.1:1, respectively. *Data not applicable because the restriction element was not present. The anti-HLA-Al and anti-HLA-A2 CTL clones
were used as positive controls (specific cell mediated colony growth inhibition > 50%), the HLA-B8 restricted mH specific CTL clone as a negative
control (specific cell-mediated colony growth inhibition < 20%).
5"Cr release assay (14±5%, n = 3). However, this clone did
not show specific growth inhibition of the leukemic-HPC and
donor-HPC from patient 11 in the cell-mediated clonogenic
assay.
Discussion
In allogeneic bone marrow transplantation, clinical observations
have indicated an antileukemic effect of donor-derived T lym-
phocytes, the GVL effect (2, 4, 32, 33). An association has been
found between the occurrence of GVHD and GVL reactivity,
although clinical observations and animal studies have indicated
that GVL may exist in the absence of GVHD (2, 32-36).
Several studies have suggested that both CD8+ and CD4+ T
lymphocytes are involved in GVHD and GVL reactivity and
may recognize polymorphic antigens in the context of HLA-
class I and class II molecules, respectively, that are processed
by the recipient cells (37-46). Previously, we have shown
that CTL clones directed against mH antigens generated from
patients with GVHD after allogeneic BMT, are capable of anti-
gen-specific lysis in vitro of freshly obtained leukemic cells, and
of antigen-specific growth inhibition of the leukemic progenitor
cells from unrelated patients (21, 22). These experiments sup-
port the hypothesis that alloreactive CTL clones directed against
polymorphic antigens presented by recipient cells can contribute
to the anti-leukemic effect.
Here, we investigated whether leukemic cells from AML
or CML patients and normal (progenitor) bone marrow cells
obtained in remission or from their HLA-identical sibling donor
can show differential susceptibility to lysis by mH CTL clones.
From the 4 CD8+ and 2 CD4+ CTL clones tested three mH
specific CTL clones, the HA-1, the HA-2 and the HA-3 specific
CTL clone showed differential recognition of the leukemic-HPC
and donor-HPC in 4 of 14 tested patient/donor combinations. In
these combinations the leukemic-HPC were recognized by the
mH specific CTL clones and the' normal HPC from the HLA-
identical donor were not recognized. Only one mH specific
CTL clone, the HA-2 specific CTL clone showed differential
recognition of the leukemic-HPC and remission-HPC from one
of the five patients. In this patient 1, expressing the HA-i and
HA-2 antigen on the leukemic-HPC the susceptibility to lysis
of the remission-HPC by the HA-2 specific CTL clone was
repeatedly (n = 3) much lower than of the leukemic-HPC. This
could not be explained by the impaired expression of the HLA
restriction molecule because the anti-HLA-A2 CTL clone and
the HLA-A2 restricted HA-1 specific CTL clones did recognize
the remission-HPC from patient 1. We recently have demon-
strated that low specific lysis of lymphocytic leukemia cells
Table VI. HLA-DR2 Restricted Specific Lysis of Leukemic Cells, Remission Bone Marrow Cells and Normal Bone Marrow Cells from the
HIA Genotypically Identical Donor
Patient 10 Patient/HLA-identical donor 11
Lysis t5'Cr release assay* Growth inhibitiont Lysis ttCr release assay* Growth inhibitiont
EBV Leu Rem-BM Leuk-HPC Rem-HPC EBV patient Leuk EBV-donor Donor-BM Leuk-HPC Donor-HPC
Clone 1 81 7 10 87 65 72 19 73 9 55 53
Clone S 49 2 9 33 2 34 14 30 2 16 18
* HLA-DR2 restricted mH specific lysis of EBV-LCL, leukemic cells (Leuk), remission bone marrow cells (Rem-BM) and donor bone marrow cells
(Donor-BM) was measured using a standard ttCr release assay in duplicate at E/T ratio 3:1. Data are expressed as percentage specific lysis. *HLA-
DR2 restricted mH specific growth inhibition of clonogenic leukemic progenitor cells (Leuk-HPC) from a patient with AML (patient 10) or CML
(patient 11) and of remission hematopoietic progenitor cells (Rem-HPC) from patient 10 or normal hematopoietic progenitor cells from the HLA-
identical donor (Donor-HPC) of patient IL. ET ratio 1:1. Both CD4 + CTL clones showed no specific lysis of control patient, HLA-DR2 positive
but not expressing the mH antigen (data not shown).
Recognition of Leukemic and Normal Cells by mH-specific T Cells 881
by the HA-2 CTL clone could be explained by a low surface
expression of these adhesion molecules as compared to targets
that were well recognized (21). The recognition by these latter
mH CTL clones could exclude the possibility of a too low
surface expression of the adhesion molecules CDl la/CD18.
Since hematopoiesis in patients with AML in remission may
be of clonal origin, clinical remission may be the persistence of
a preleukemic clone during remission (47-49). To investigate
whether a possible preleukemic hematopoiesis of the remission-
BM may explain similarities in recognition of remission and
leukemic precursor cells, mH specific recognition of the remis-
sion-BM was compared to the recognition of the bone marrow
from the HLA-identical sibling donor. From the 3 HLA-identi-
cal sibling pairs tested (AML patient 1, 2 and 3) in one pair
differential recognition was observed (data not shown). The
remission-HPC from patient 2 were strongly lysed by the HA-
2 specific CTL clone, but only minor recognition of the HPC
from the HLA-identical sibling donor was observed. Since also
from 1 patient the leukemic cells were more susceptible to
lysis than the normal HPC, these results may suggest that a
preleukemic hematopoiesis of the remission-BM may be the
cause of the relatively high lysis of the remission-BM as com-
pared to the donor bone marrow. On the other hand differential
susceptibility to lysis by the HA-2 specific clone due to genetic
predisposition may a more likely explanation for this phenom-
ena. Since low specific lysis of normal HPC's by the HA-2
CTL clone was also observed by Marijt et al in 2 of 6 normal
healthy bone marrow donors this differential susceptibility to
lysis may be explained by a genetic difference in HA-2 antigen
expression (25).
From the two tested CD4+ CTL clones clone 11 showed
specific lysis of the leukemic-HPC from an AML patient and
CML patient as well as of normal remission-HPC and donor-
HPC respectively. Since the specific lysis of these targets was
low in the 54Cr release assay these results confirm the high
sensitivity of the clonogenic assay as a tool for the study of
cellularly defined antigens on HPC's (31). Clone S, the CD4+
CTL clone that recognizes in vitro transformed EBV-LCL from
DR2 positive individuals and some (EBV negative) AML sam-
ples did not show specific growth inhibition of the leukemic-
HPC and HPC's from both patients in the clonogenic assay.
However this clone did recognize both the leukemic cells and
EBV-LCL from the AML patient against whom this CTL clone
was generated (29). Since the EBV-LCL from the HLA-geno-
typically identical donor of this AML patient were also recog-
nized, the antigen recognized by clone S appeared not to be a
classic mH antigen and is still unclear.
From these data we conclude that in general mH specific
CTL clones (CD8+ and CD4+ CTL clones) do not differen-
tially recognize leukemic-HPC and normal HPC. This is in
agreement of studies performed in animals indicating that mH
antigen specific CTL do not discriminate between normal and
malignant hematopoietic cells (12). The differential suscepti-
bility to lysis of leukemic-HPC from the recipient and the donor-
HPC in 4 patient/donor combinations by the HA-1, HA-2, or
HA-3 specific CTL clones may explain a GVL reactivity after
allogeneic BMT. In our experiments recognition of specific tar-
get organs involved in GVHD by the mH CTL clones has not
been tested. Recently a study has been performed to determine
the expression of human mH antigens on various tissues (26).
The minor antigens HA-3, -4, -6, -7, and HY were detected on
all tissues tested (PHA-blasts, EBV-LCL, purified T cells, B
cells, monocytes, immature thymocytes, skin-derived cultured
fibroblasts, keratinocytes, melanocytes, cultured epithelial cells
of kidney proximal tubuli and umbilical cord vein derived endo-
thelial cells), but HA-1 and HA-2 could only be demonstrated
on cell types of hematopoietic origin. Therefore, both mH spe-
cific CTL clones recognizing mH expressed to a high extent on
leukemic-HPC as compared to normal HPC, and clones recog-
nizing mH that are only expressed on hematopoietic cells, may
be relevant for the suppression of leukemia relapses after alloge-
neic BMT.
In conclusion, our results indicated that in general mH-
specific CTL clones do not differentially recognize leukemic
HPC and normal HPC, nor do the leukemic HPC exhibit a
differential sensitivity to lysis or growth inhibition that discrimi-
nates them from normal hematopoietic cells. However, in a
minority of the cases studied, differential susceptibility of leuke-
mic cells over normal hematopoietic cells can be demonstrated.
Thus, in some patients such mH-specific CTL clones may con-
tribute to a differential GvL effect.
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